Th17/Treg-Related Intracellular Signaling in Patients with Chronic Obstructive Pulmonary Disease: Comparison between Local and Systemic Responses

Imagem de Miniatura
Arquivos
art_LOURENCO_Th17TregRelated_Intracellular_Signaling_in_Patients_with_Chronic_Obstructive_2021.PDF (3.38 MB)
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
Citação
CELLS, v.10, n.7, article ID 1569, 15p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Th17/Treg imbalance plays a pivotal role in COPD development and progression. We aimed to assess Th17/Treg-related intracellular signaling at different COPD stages in local and systemic responses. Lung tissue and/or peripheral blood samples were collected and divided into non-obstructed (NOS), COPD stages I and II, and COPD stages III and IV groups. Gene expression of STAT3 and -5, ROR gamma t, Foxp3, interleukin (IL)-6, -17, -10, and TGF-beta was assessed by RT-qPCR. IL-6, -17, -10, and TGF-beta levels were determined by ELISA. We observed increased STAT3, ROR gamma t, Foxp3, IL-6, and TGF-beta gene expression and IL-6 levels in the lungs of COPD I and II patients compared to those of NOS patients. Regarding the systemic response, we observed increased STAT3, ROR gamma t, IL-6, and TGF-beta gene expression in the COPD III and IV group and increased IL-6 levels in the COPD I and II group. STAT5 was increased in COPD III and IV patients, although there was a decrease in Foxp3 expression and IL-10 levels in the COPD I and II and COPD III and IV groups, respectively. We demonstrated that an increase in Th17 intracellular signaling in the lungs precedes this increase in the systemic response, whereas Treg intracellular signaling varies between the compartments analyzed in different COPD stages.
Palavras-chave
COPD, Treg, Th17, STAT, intracellular signaling
URI
https://observatorio.fm.usp.br/handle/OPI/41268
Referências
  1. Abbas A.K., 2018, CELL MOL IMMUNOL, P57
  2. Agusti Alvar, 2007, Proc Am Thorac Soc, V4, P522, DOI 10.1513/pats.200701-004FM
  3. Agusti A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037483
  4. Baarsma HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025450
  5. Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008
  6. Barnes PJ, 2014, CLIN CHEST MED, V35, P71, DOI 10.1016/j.ccm.2013.10.004
  7. Brusselle GG, 2011, LANCET, V378, P1015, DOI 10.1016/S0140-6736(11)60988-4
  8. Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280
  9. Caramori G, 2016, SEMIN IMMUNOPATHOL, V38, P497, DOI 10.1007/s00281-016-0561-5
  10. Chen WJ, 2010, J MOL CELL BIOL, V2, P30, DOI 10.1093/jmcb/mjp004
  11. Chu SY, 2011, INT IMMUNOPHARMACOL, V11, P1780, DOI 10.1016/j.intimp.2011.06.010
  12. Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752
  13. Di Stefano A, 2009, CLIN EXP IMMUNOL, V157, P316, DOI 10.1111/j.1365-2249.2009.03965.x
  14. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020, REP GLOB INIT CHR OB REP GLOB INIT CHR OB
  15. Jin Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111044
  16. Junqueira J.J.M., 2020, COPD, DOI [10.1080/15412555.2020.1808605, DOI 10.1080/15412555.2020.1808605]
  17. Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
  18. Lane N, 2010, CLIN SCI, V119, P75, DOI 10.1042/CS20100033
  19. Li HJ, 2015, AM J MED SCI, V349, P392, DOI 10.1097/MAJ.0000000000000447
  20. Li XN, 2014, INT J CLIN EXP MED, V7, P5324
  21. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  22. Marshall EA, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0551-1
  23. Plumb J, 2009, EUR RESPIR J, V34, P89, DOI 10.1183/09031936.00100708
  24. Podowski M, 2012, J CLIN INVEST, V122, P229, DOI 10.1172/JCI46215
  25. Qu P, 2009, LUNG CANCER, V63, P341, DOI 10.1016/j.lungcan.2008.05.025
  26. Sales DS, 2017, COPD, V14, P533, DOI 10.1080/15412555.2017.1346069
  27. Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y
  28. Sileikiene V, 2019, ADV RESPIR MED, V87, P159, DOI 10.5603/ARM.2019.0023
  29. Silva BSA, 2018, CYTOKINE, V106, P95, DOI 10.1016/j.cyto.2017.10.018
  30. Sinden NJ, 2010, THORAX, V65, P930, DOI 10.1136/thx.2009.130260
  31. Wang HY, 2015, CLIN RESPIR J, V9, P330, DOI 10.1111/crj.12147
  32. Wang ZY, 2019, PHYTOTHER RES, V33, P808, DOI 10.1002/ptr.6274
  33. WHO, 2018, PROJ MORT CAUS DEATH
  34. Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437
  35. Yang YC, 2012, ALLERGY, V67, P1193, DOI 10.1111/j.1398-9995.2012.02880.x
  36. Yew-Booth L, 2015, EUR RESPIR J, V46, P843, DOI 10.1183/09031936.00228414
  37. Zhang L, 2013, COPD, V10, P459, DOI 10.3109/15412555.2013.770456

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/02
Artigos e Materiais de Revistas Científicas - LIM/05
Carregar mais